Sangamo BioSciences (SGMO) drops 36.8% premarket after announcing it didn't meet the clinical...


Sangamo BioSciences (SGMO) drops 36.8% premarket after announcing it didn't meet the clinical endpoints it hoped to achieve in a Phase 2b trial of its SB-509 drug for treating diabetic neuropathy. As a result, Sangamo plans to discontinue development of SB-509.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs